Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
|
Homo sapiens
|
570.0
nM
|
|
Growth inhibition of human T24 cells after 4 days by MTT assay
|
Homo sapiens
|
23.8
%
|
|
Inhibition of Torpedo californica AChE
|
Torpedo californica
|
26.4
nM
|
|
Inhibition of human AChE
|
Homo sapiens
|
50.5
nM
|
|
Cytotoxicity against human KB3-1 cells by MTT method
|
Homo sapiens
|
680.0
nM
|
|
Antitumor activity against human SJSA1 cells xenografted in mouse assessed as tumor growth inhibition at 100 mg/kg, ip dosed once weekly for two weeks relative to untreated control
|
Homo sapiens
|
0.0002
%
|
|
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
15.0
nM
|
|
Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
4.0
nM
|
|
Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
220.0
nM
|
|
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
100.0
nM
|
|
Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
4.0
nM
|
|
Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
200.0
nM
|
|
Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
200.0
nM
|
|
Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
9.0
nM
|
|
Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
30.0
nM
|
|
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA
|
Homo sapiens
|
27.0
nM
|
|
Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
10.0
nM
|
|
Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay
|
Homo sapiens
|
22.0
nM
|
|
Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay
|
Homo sapiens
|
22.0
nM
|
|
Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay
|
Homo sapiens
|
250.0
nM
|
|
Cytotoxicity against human bone marrow cell by CFU-GM assay
|
Homo sapiens
|
110.0
nM
|
|
Cytotoxicity against mouse bone marrow cell by CFU-GM assay
|
Mus musculus
|
1.0
nM
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
None
|
217.0
nM
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
|
None
|
461.0
nM
|
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting
|
Homo sapiens
|
40.5
%
|
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
26.9
%
|
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
16.3
%
|
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay
|
Homo sapiens
|
49.0
%
|
|
Inhibition of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control
|
Homo sapiens
|
34.3
%
|
|
Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay
|
Homo sapiens
|
900.0
nM
|
|
Antiproliferative activity against human PC3 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay
|
Homo sapiens
|
800.0
nM
|
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay
|
Homo sapiens
|
900.0
nM
|
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTS assay
|
Homo sapiens
|
800.0
nM
|
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTS assay
|
Homo sapiens
|
500.0
nM
|
|
Antiproliferative activity against human HepG2 cells at 10 uM after 24 hrs by MTS assay relative to control
|
Homo sapiens
|
98.9
%
|
|
Antiproliferative activity against human A549 cells at 10 uM after 24 hrs by MTS assay relative to control
|
Homo sapiens
|
91.8
%
|
|
Antiproliferative activity against human MCF7 cells at 10 uM after 24 hrs by MTS assay relative to control
|
Homo sapiens
|
93.6
%
|
|
Antiproliferative activity against human SW480 cells at 10 uM after 24 hrs by MTS assay relative to control
|
Homo sapiens
|
95.0
%
|
|
Antiproliferative activity against human Maver2 cells after 72 hrs by MTT assay
|
Homo sapiens
|
740.0
nM
|
|
Antitumor activity against human MM473 cells xenografted in CD1 nude mouse assessed as inhibition of tumor volume at 20 mg/kg, iv administered every 4 days per week for 3 weeks measured 10 days post last dose by luciferase reporter assay relative to vehicle-treated control
|
Homo sapiens
|
37.0
%
|
|
Cytotoxicity against human MCF7 cells incubated for 24 hrs by MTT assay
|
Homo sapiens
|
800.0
nM
|
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
Homo sapiens
|
498.0
nM
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
121.15
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.01
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.01
%
|
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
Homo sapiens
|
32.0
nM
|
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
Homo sapiens
|
32.0
nM
|
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
Homo sapiens
|
32.0
nM
|
|
Antitumor activity against human SK-OV-3 cells xenografted in BALB/c nude mouse assessed as reduction in tumor volume at 20 mg/kg, iv once a week for 3 weeks relative to control
|
Homo sapiens
|
53.5
%
|
|
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
Homo sapiens
|
4.4
nM
|
|
Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
Homo sapiens
|
5.1
nM
|
|
Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
Homo sapiens
|
6.9
nM
|
|
Cytotoxicity against human MCF7 cells by MTT assay
|
Homo sapiens
|
800.0
nM
|
|
Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
Homo sapiens
|
490.0
nM
|
|